Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | NMT2 | O60551 | 2/20 | 0.34 |
| ▸ | NMT1 | P30419 | 2/20 | 0.34 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.34 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.34 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.34 |
| ▸ | GLP1R | P43220 | 8/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16790725 | 1.00 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2SIRT6SIRT1NMT2 | |
| SCHEMBL16790753 | 0.95 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2SIRT6SIRT1NMT2 | |
| SCHEMBL19441334 | 0.93 | MEN1 (0.39) | ALDH1A1SMN1; SMN2SIRT6SIRT1NMT2 | |
| SCHEMBL16790756 | 0.91 | MEN1 (0.43) | ALDH1A1SMN1; SMN2SIRT6SIRT1NMT2 | |
| SCHEMBL19441333 | 0.90 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2SIRT6SIRT1NMT2 | |
| SCHEMBL13196276 | 0.90 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2SIRT6SIRT1NMT2 | |
| SCHEMBL13196250 | 0.87 | SIRT6 (0.37) | ALDH1A1SMN1; SMN2SIRT6SIRT1NMT2 | |
| SCHEMBL16789169 | 0.87 | SIRT6 (0.37) | ALDH1A1SMN1; SMN2SIRT6SIRT1NMT2 | |
| SCHEMBL16789194 | 0.83 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2SIRT6SIRT1NMT2 | |
| SCHEMBL13196269 | 0.83 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2SIRT6SIRT1NMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783571-B2 | Isolation of cysteine containing peptides | MARTIN WARHAM LANCE (US) | 2017-10-10 | — | — | US | disclosed |
| US-20150158905-A1 | Isolation of Cysteine Containing Peptides | MARTIN WARHAM LANCE (US) | 2015-06-11 | — | — | US | disclosed |
| WO-2012138920-A1 | ISOLATION OF CYSTEINE CONTAINING PEPTIDES | MARTIN-PROTEAN, LLC (US) | 2012-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158905-A1 | Isolation of Cysteine Containing Peptides | LNPEP, CSTB, CPB1 | ALDH1A1 4198/4885SMN1; SMN2 3838/4885SIRT6 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.